Sequence: stearyl-HEHHEHHEHEHGFLGRVRVLRGDKW-amide
| Experiment Id | EXP000542 |
|---|---|
| Paper | A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV- |
| Peptide | HE25 |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | 0.2–1 mg/kg |
| Mixing Ratio | 1:40 or 1:100 |
| Formulation Format | Systemic peptide–siRNA complex |
| Formulation Components | HE25–siRNA self-assembled complex |
| Size Nm | 100.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | CIEA NOG mice; BALB/c mice |
| Administration Route | IV (tail vein) and nose-to-lung inhalation |
| Output Type | Biodistribution (SPECT/CT, confocal); lung gene silencing surrogate; safety |
| Output Value | Strong lung accumulation; endothelial vs epithelial localization route-dependent; no weight loss or fibrosis |
| Output Units | |
| Output Notes | In vivo biodistribution demonstrated; no in vivo viral challenge efficacy study performed |
| Toxicity Notes | No acute toxicity; no lung fibrosis or weight loss |
| Curation Notes |